About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group aims to unravel the molecular mechanisms of cancer progression and metastasis to identify new diagnostic, prognostic and therapeutic targets in cancer. By combining the knowledge and availability of human tumors in the Pathology department with the expertise of the basic molecular cell biology research group, we focus on:
This is a research and teaching line in porcine model of laparoscopy. The influence of pneumo-peritoneum and ischemia in kidney function has been main objectives in the past. Now, the use of bioengineering materials in bladder substitution is the main objective of this line.
IP: Carles Xavier Raventós Busquets
Studying in colorectal cancer mechanisms of action of the central signal transduction pathways, identify potential molecular alterations that can be used as therapeutic targets and characterize the degree of genetic inestability.
IP: Santiago Ramon y Cajal Agüeras
We have characterized the levels of activation in Cell Signalling in a spectrum of solid tumors and correlated the levels of various factors, including mTOR and downstream proteins (p70S6K, S6, 4EBP1, eIF4E) with prognosis and grade of malignancy. Also, are being characterized, at the molecular level, the factors involved in controlling the translation cap dependent and independent in malignant tumors.
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
Check the current rates for the services offered by the Translational Molecular Pathology research group.
Current Rates
PDF 0.25 MB
Rates Anatomia Patologica VHIR 2021
PDF 0.22 MB
